Cingulate Inc.今日宣布,其候选药物Ctx-1301在III期临床试验的主要终点上,取得了相较安慰剂具有统计学显著意义的改善。这一积极数据,为这款备受瞩目的实验性疗法注入了强劲动力。
Cingulate Inc.今日宣布,其候选药物Ctx-1301在III期临床试验的主要终点上,取得了相较安慰剂具有统计学显著意义的改善。这一积极数据,为这款备受瞩目的实验性疗法注入了强劲动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.